Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

Blood

Volumn 110, Issue 2, 2007, Pages 787-788

  Palladini, Giovanni ^b   Russo, Paola ^b   Nuvolone, Mario ^b   Lavatelli, Francesca ^b   Perfetti, Vittorio ^b   Obici, Laura ^b   Merlini, Giampaolo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

AMYLOIDOSIS; CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG COST; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; SURVIVAL; TREATMENT PLANNING;

EID: 34547137414     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-02-076034     Document Type: Letter

References (6)

1. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
2. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004;34:1025-1031.
3. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103:2936-2938.
4. Jaccard A, Moreau P, Leblond V, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French Multicentric Randomized Trial (MAG and IFM intergroup) [abstract]. Blood. 2005;106:421a.
5. Goodman HJ, Hawkins PN, Dispenzieri A, et al. The role of PBSCT in treatment of AL amyloidosis is far from settled. Blood. 2004;104:2991-2994.
6. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105:2949-2951.